Skip to content
PeptideAgent

Clinics in Maryland

By the PeptideAgent Editorial Team. Draft, pending editorial review.  Last verified

What Maryland law means for peptide clinics: who may prescribe, whether pharmacies may compound GLP-1 drugs (limited), how to check a clinic, and verified listings.

Maryland at a glance

503A framework
Follows the federal 503A framework
Telehealth prescribing
Regulatory: Telehealth allowed
Asynchronous prescribing
Regulatory: Async allowed
Compounded GLP-1 access
Regulatory: Compounded GLP-1 limited

Verified clinics serving Maryland

No verified clinics serving Maryland are listed yet. A provider appears here only after it passes the verification checklist, and those checks are still under way.

Looking for care now? Start with what the law allows where you live, then how a legitimate prescription works.

Run a pharmacy, clinic, or telehealth service? Apply for a listing.

Peptide access rules in Maryland

Yes. A Maryland resident can obtain FDA approved peptides such as semaglutide and tirzepatide from a Maryland-licensed prescriber, including through telehealth, and Maryland's telehealth statute (Health Occupations Article, section 1-1001 and following) expressly lets a practitioner perform the clinical evaluation required before treatment through either a synchronous or an asynchronous interaction. A compounded peptide is available when it is eligible under federal 503A rules and dispensed by a pharmacy holding a Maryland pharmacy permit; out-of-state pharmacies need a Maryland nonresident pharmacy permit, which requires a recent home-state inspection report and a Maryland agent for service of process. [1] [2] [3] [4] [5] [6] [7] [8] [10]

Compounded GLP-1 access in Maryland

Maryland's asynchronous telehealth rule makes app-based GLP-1 programs lawful on the prescribing side, but the dispensing pharmacy must still hold a Maryland pharmacy or nonresident pharmacy permit. [3] [5] [11]

Research use only sellers in Maryland

Maryland's Food, Drug, and Cosmetic Act (Health-General Article, Title 21) prohibits selling adulterated or misbranded drugs, and Health Occupations Title 12 limits dispensing of prescription drugs to permitted pharmacies and authorized practitioners. [1] [9] [12]

How to check a clinic in Maryland

  1. Confirm the prescribing clinician's license with the Maryland medical or nursing board.
  2. Ask which pharmacy compounds or dispenses the peptide and check it in the Maryland Board of Pharmacy (Maryland Department of Health) license lookup. [1] [5] [6] [7] [8] [10]
  3. Confirm the peptide can be lawfully compounded: check its status on the regulatory tracker or its peptide page before paying.
  4. Walk away from any seller that labels a peptide "research use only" or "not for human consumption". See the research use only section above for what that means in Maryland. [1] [9] [12]

Common questions in Maryland

Can I get a GLP-1 prescription in Maryland from an online questionnaire or app?

Maryland law allows it in principle. Health Occupations section 1-1003 lets a Maryland-licensed practitioner perform the required clinical evaluation through an asynchronous telehealth interaction, and the care must meet the in-person standard. The prescriber still decides whether the information is enough to prescribe safely. [2] [3]

Does a telehealth prescriber need a Maryland license?

Yes. Maryland's telehealth statute applies to practitioners licensed in Maryland, and the Board of Physicians' telehealth regulations in COMAR 10.32.05 require Maryland licensure to treat a patient located in Maryland. [2] [4]

All peptide legal questions for Maryland

Sources

  1. [1]Maryland Board of Pharmacy
  2. [2]Maryland Code, Health Occupations section 1-1001, Telehealth definitions
  3. [3]Maryland Code, Health Occupations section 1-1003, Telehealth clinical evaluation and prescribing
  4. [4]COMAR 10.32.05, Telehealth (Maryland Board of Physicians)
  5. [5]Maryland Code, Health Occupations section 12-403, Required standards (including nonresident pharmacies)
  6. [6]COMAR Title 10, Subtitle 34, Board of Pharmacy regulations
  7. [7]COMAR 10.34.37.04, Requirements for nonresident pharmacy operations
  8. [8]Maryland Senate Bill 69 (2015), Chapter 5: repeal of the sterile compounding permit requirement
  9. [9]Maryland Code, Health-General Title 21, Food, Drugs, and Cosmetics
  10. [10]FDA: Section 503A of the Federal Food, Drug, and Cosmetic ActFDA
  11. [11]FDA: concerns with unapproved GLP-1 drugs used for weight loss, including shortage resolution and compounding grace periodsFDA
  12. [12]21 U.S.C. 331, Prohibited acts